JAKAFI (Incyte Corporation)
Welcome to the PulseAid listing for the JAKAFI drug offered from Incyte Corporation. This Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Incyte Corporation |
| NON-PROPRIETARY NAME: | ruxolitinib |
| SUBSTANCE NAME: | RUXOLITINIB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2011-11-16 |
| END MARKETING DATE: | 0000-00-00 |
JAKAFI HUMAN PRESCRIPTION DRUG Details:
| Item Description | JAKAFI from Incyte Corporation |
| LABELER NAME: | Incyte Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 5(mg/1) |
| START MARKETING DATE: | 2011-11-16 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 50881-005_f656a43c-f8cc-4882-84bd-09d5aaf5b054 |
| PRODUCT NDC: | 50881-005 |
| APPLICATION NUMBER: | NDA202192 |
Other RUXOLITINIB Pharmaceutical Manufacturers / Labelers:
